S Eswara Reddy rejoins as joint drug controller after Centre revokes suspension

After the Union government revoked his suspension on December 26, former Joint Drug Controller S Eswara Reddy has rejoined the apex drug regulatory body.

The Delhi High Court granted bail to both Reddy and Biocon’s associate vice-president Praveen Kumar.

According to the CBI, three people were arrested in June after they were allegedly bribed to waive off a clinical trial requirement for a diabetes drug developed by Biocon Biologicals. The company, a Biocon subsidiary, has denied the charges.

Reddy was arrested on June 21 for allegedly taking a bribe to waive off the phase-3 clinical trial of the Insulin Aspart injection of Biocon Biologics. On July 19, a CBI court in Delhi rejected his bail application and those of Biocon Biologics’ Associate Vice President L Praveen Kumar and three others.

Reddy alleged that the proceedings were “part of some larger conspiracy not to let him appear for the interview for the above post (DCGI) though despite (CBI) proceedings, no departmental enquiry has been instituted against him”.

He didn’t elaborate on the conspiracy or those who were part of it.

He also told the court that due to his “impeccable career and character”, he was appointed interim Drug Controller of India from February 2018 to August 2019 and was likely to be appointed as such.

Opposing the bail plea, the CBI said they caught Reddy while he was accepting Rs 4 lakh from Dinesh Dua, director at Synergy Network India Private Limited.

Related Posts

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

Lilly takes 6 companies to court for selling retatrutide knockoffs

Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Lilly takes 6 companies to court for selling retatrutide knockoffs

Lilly takes 6 companies to court for selling retatrutide knockoffs

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch